On Aug. 25, 2020, AstraZeneca announced that the first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19.

The trial, called NCT04507256, was to evaluate the safety, tolerability and pharmacokinetics of AZD7442. The trial planned to include up to 48 healthy participants in the UK aged 18 to 55 years.